OICR-9429

Catalog No.S7833 Batch:S783305

Print

Technical Data

Formula

C29H32F3N5O3
Molecular Weight 555.59 CAS No. 1801787-56-3
Solubility (25°C)* In vitro DMSO 100 mg/mL (179.98 mM)
Ethanol 8 mg/mL (14.39 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
0.8mg/ml Taking the 1 mL working solution as an example, add 50 μL of 16 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description OICR-9429 is a potent antagonist of the interaction of WDR5 with peptide regions of MLL and Histone 3 and reduces viability of acute myeloid leukemia cells in vitro. It binds to WDR5 with high affinity (KD = 93 ± 28 nM.
Targets
Wdr5-MLL interaction [1] WDR5 [1]
93 nM(Kd)
In vitro

OICR-9429 binds WDR5 with high affinity (Kd=93±28 nM) and competitively disrupts its interaction with a high-affinity Wdr5-interacting (WIN) peptide of MLL (Kdisp=64±4 nM)[1].
In vivo

OICR-9429, a potent WDR5 inhibitor, suppressed proliferation, metastasis and PD-L1-based immune evasion while enhancing apoptosis and chemosensitivity to cisplatin in bladder cancer by blocking the WDR5-MLL complex mediating H3K4me3 in target genes.

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    Primary human AML cells

  • Concentrations

    5 μM

  • Incubation Time

    72 h

  • Method

    20,000 viable, actively proliferating primary human AML cells per well were seeded in 96-well plates in triplicates and treated with 0.05% DMSO or OICR-9429. Cell viability was measured using the Cell Titer-Glo luminescent cell viability assay on a VICTOR X4 luminometer after 72 h.
Animal Study:

[2]
  • Animal Models

    Male BALB/c nude mice

  • Dosages

    30 or 60 mg/kg

  • Administration

    i.p.

Customer Product Validation

Data from [Data independently produced by , , Theranostics, 2018, 8(18):5143-5158]

Selleck's OICR-9429 has been cited by 13 publications

MYCN drives oncogenesis by cooperating with the histone methyltransferase G9a and the WDR5 adaptor to orchestrate global gene transcription [ PLoS Biol, 2024, 22(3):e3002240] PubMed: 38547242
The COMPASS complex maintains the metastatic capacity imparted by a subpopulation of cells in UPS [ iScience, 2024, 27(7):110187] PubMed: 38989451
Therapeutic targeting of metabolic vulnerabilities in cancers with MLL3/4-COMPASS epigenetic regulator mutations [ J Clin Invest, 2023, 133(13)e169993] PubMed: 37252797
Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells [ EBioMedicine, 2023, 92:104602] PubMed: 37148583
Unannotated microprotein EMBOW regulates the interactome and chromatin and mitotic functions of WDR5 [ Cell Rep, 2023, 42(9):113145] PubMed: 37725512
MYCN driven oncogenesis involves cooperation with WDR5 to activate canonical MYC targets and G9a to repress differentiation genes [ bioRxiv, 2023, 2023.07.11.548643] PubMed: 37781575
MYCN driven oncogenesis involves cooperation with WDR5 to activate canonical MYC targets and G9a to repress differentiation genes [ bioRxiv, 2023, 2023.07.11.548643] PubMed: 37781575
Recruitment of MLL1 complex is essential for SETBP1 to induce myeloid transformation [ iScience, 2022, 25(1):103679] PubMed: 35036869
ecDNA hubs drive cooperative intermolecular oncogene expression [ Nature, 2021, 10.1038/s41586-021-04116-8] PubMed: 34819668
Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer [ J Exp Clin Cancer Res, 2021, 40(1):203] PubMed: 34154613

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.